Daewoong Pharma Enters Technology Introduction Contract for Semaglutide Long-Acting Injectable (Conditional, Amount Undisclosed)

Daewoong Pharma entered into a technology introduction contract with Tion Lab Therapeutics for a semaglutide-based 4-week long-acting injectable (depot formulation) for obesity treatment
The contract is conditional and may be terminated if clinical or regulatory approval fails
Daewoong Pharma obtains exclusive rights for development, manufacturing, approval, and commercialization globally excluding South Korea, with sublicensing rights
Contract date is May 21, 2026; contract term ends 15 years from first commercial sale or patent expiry, whichever is later
Financial terms (upfront, milestones, royalties) are undisclosed for confidentiality, with a disclosure hold until patent expiry on August 19, 2044
Core technology is based on a patent for 'initial release controlled depot composition and manufacturing method'

ADVERTISEMENT (250px+)

Filing: Material Information On Investment Decision (Execution Of Technology Introduction Agreement For Semaglutide For Obesity Treatment (4-Week Long-Acting Injectable))
Company: Daewoong Pharma (069620)
Submission: Daewoong Pharma
Receipt: 05-21-2026
Under KRX KOSPI Market Division